type 1 diabetes and glp-1 vs. GLP-1 + GIP: What's the Difference for your Metabolism? More people with type 1

Adv Ther 38 , 468478 (2021)

TABLE 2 The Dietary source - gut microbiota metabolites axis that promotes diseases

Heres what stands out 1 Two Phase 2 wins, two different proof points Elecoglipron was evaluated in: #VISTA (Phase 2) 36-week weight-loss study vs placebo in 310 patients with obesity or overweight #SOLSTICE (Phase 2) glycemic control study vs placebo or semaglutide (active ingredient in Novo Nordisks #Wegovy) in 406 Type 2 diabetes patients Both studies hit their primary endpoints, clearing the bar for Phase 3

The role of diet in psoriasisa chronic systemic inflammatory disease

Third-Party Testing Available: Independent verification upon request